Evidence map›Paper›PMID 39900943›Full record

ArticleScientific reports2025

Reducing M2 macrophage in lung fibrosis by controlling anti-M1 agent.

Fatemeh Bahram Yazdroudi, Alaeddin Malek

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Monocyte-Derived LGMNResearch (Washington, D.C.) · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fatemeh Bahram YazdroudiDepartment of Applied Mathematics, Faculty of Mathematical Sciences, Tarbiat Modares University, Tehran, Iran.
Alaeddin MalekDepartment of Applied Mathematics, Faculty of Mathematical Sciences, Tarbiat Modares University, Tehran, Iran. mala@modares.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by excessive scarring and fibrosis due to the abnormal accumulation of extracellular matrix components, primarily collagen. This study aims to design and solve an optimal control problem to regulate M2 macrophage activity in IPF, thereby preventing fibrosis formation by controlling the anti-M1 agent. The research models the diffusion of M2 macrophages in inflamed tissue using a novel dynamical system with partial differential equation (PDE) constraints. The control problem is formulated to minimize fibrosis by regulating an anti-M1 agent. The study employs a two-step process of discretization followed by optimization, utilizing the Galerkin spectral method to transform the M2 diffusion PDE into an algebraic system of ordinary differential equations (ODEs). The optimal control problem is then solved using Pontryagin/s minimum principle, canonical Hamiltonian equations, and extended Riccati differential equations. The numerical simulations indicate that without control, M2 macrophage levels increase and stabilize, contributing to fibrosis. In contrast, the optimal control strategy effectively reduces M2 macrophages, preventing fibrosis formation within 120 days. The results highlight the potential of the proposed optimal control approach in modulating tissue repair processes and mitigating the progression of IPF. This study underscores the significance of targeting M2 macrophages and employing mathematical methods to develop innovative therapies for lung fibrosis.

Indexed as

Idiopathic Pulmonary FibrosisMacrophagesHumansLungMacrophage ActivationModels, BiologicalAnti-M1 agentCanonical HamiltonianDiffusion equationDynamical systemExtended Riccati equationsLung fibrosisM2 macrophagesOptimal regulator problem

Identifiers

PMID39900943
PMCPMC11791193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.